What is Filana Therapeutics's earnings per share (EPS)?

Filana Therapeutics (FLNA) reported diluted earnings per share of $-1.88 for fiscal year 2025. This represents a -28.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Filana Therapeutics Financials

FLNA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Filana Therapeutics (FLNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FLNA FY2025 2026-05-07

Filana's cash burn improved, but the cost base turned overhead-heavy while liquidity thinned in FY2025.

In FY2025, net loss and cash burn reconnected: net loss was -$91.0M while operating cash outflow was -$32.3M. In FY2024, cash burn of -$116.9M dwarfed the -$24.3M net loss, so that year's earnings understated cash use; FY2025's reported loss is a much cleaner picture of what the business actually consumed.

The operating loss improved to -$95.4M in FY2025, but R&D fell to $26.6M while SG&A stayed elevated at $68.8M. For a company with no reported revenue, that mix means lower burn came more from dialing back development activity than from truly shrinking the organizational cost base.

The balance sheet remains debt-light, yet liquidity tightened materially as cash fell to $95.5M and the current ratio dropped to 2.2x. Liabilities rose to $44.0M, and with financing cash flow near zero after a $124.5M FY2024 inflow, FY2025 was funded mainly by spending down previously raised capital rather than replenishing it.

Financial Health Signals

Financial health score pending refresh

We are recalculating Filana Therapeutics's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Filana Therapeutics passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.35x

For every $1 of reported earnings, Filana Therapeutics generates $0.35 in operating cash flow (-$32.3M OCF vs -$91.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$94.5M

YoY+32.7%

Filana Therapeutics's EBITDA was -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.7% from the prior year.

Net Income

-$91.0M

YoY-273.7%

Filana Therapeutics reported -$91.0M in net income in fiscal year 2025. This represents a decrease of 273.7% from the prior year.

EPS (Diluted)

$-1.88

YoY-28.8%

Filana Therapeutics earned $-1.88 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 28.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$32.8M

YoY+71.9%

Filana Therapeutics generated -$32.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 71.9% from the prior year.

Cash & Debt

$95.5M

YoY-25.7%

5Y CAGR+0.4%

10Y CAGR+11.8%

Filana Therapeutics held $95.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

48M

YoY+0.2%

5Y CAGR+6.5%

Filana Therapeutics had 48M shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-122.3%

YoY-105.6pp

5Y CAGR-115.4pp

10Y CAGR-74.1pp

Filana Therapeutics's ROE was -122.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 105.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$26.6M

YoY-61.8%

10Y CAGR+11.3%

Filana Therapeutics invested $26.6M in research and development in fiscal year 2025. This represents a decrease of 61.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$581K

YoY+464.1%

10Y CAGR+11.5%

Filana Therapeutics invested $581K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 464.1% from the prior year.

FLNA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$26.6M-61.8%	$69.6M-22.1%	$89.4M+31.4%	$68.0M+174.2%	$24.8M	N/A
SG&A Expenses	$68.8M-4.2%	$71.8M+334.3%	$16.5M+37.9%	$12.0M+48.8%	$8.1M+115.4%	$3.7M
Operating Income	-$95.4M+32.6%	-$141.4M-33.5%	-$106.0M-32.4%	-$80.0M-143.5%	-$32.9M-409.9%	-$6.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	-$91.0M-273.7%	-$24.3M+75.0%	-$97.2M-27.5%	-$76.2M-135.4%	-$32.4M-411.3%	-$6.3M
EPS (Diluted)	$-1.88-28.8%	$-1.46+37.1%	$-2.32-22.1%	$-1.90	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.5M	N/A	$4.0M-22.7%	$5.1M-62.6%	$13.7M	N/A	$17.7M+16.3%	$15.2M
SG&A Expenses	$6.6M	N/A	$7.9M-80.4%	$40.3M+268.8%	$10.9M	N/A	$12.9M-72.0%	$46.2M
Operating Income	-$11.2M	N/A	-$11.9M+73.9%	-$45.4M-84.6%	-$24.6M	N/A	-$30.6M+50.1%	-$61.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$10.3M	N/A	-$10.8M+75.6%	-$44.2M-89.0%	-$23.4M	N/A	-$27.9M-554.0%	$6.2M
EPS (Diluted)	N/A	N/A	$-0.22+76.1%	$-0.92-91.7%	$-0.48	N/A	$-0.58-546.2%	$0.13

FLNA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$118.4M-24.9%	$157.5M+3.9%	$151.7M-35.4%	$234.8M-12.0%	$266.8M+182.9%	$94.3M
Current Assets	$97.7M-28.4%	$136.5M+5.3%	$129.6M-38.6%	$211.2M-13.6%	$244.5M+160.1%	$94.0M
Cash & Equivalents	$95.5M-25.7%	$128.6M+6.1%	$121.1M-39.7%	$201.0M-13.9%	$233.4M+149.6%	$93.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$44.0M+271.6%	$11.8M-16.7%	$14.2M+94.6%	$7.3M-43.3%	$12.9M+512.7%	$2.1M
Current Liabilities	$43.8M+273.1%	$11.8M-17.2%	$14.2M+101.0%	$7.1M-43.6%	$12.5M+572.1%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$74.4M-48.9%	$145.7M+6.0%	$137.5M-39.6%	$227.5M-10.4%	$253.9M+175.4%	$92.2M
Retained Earnings	-$496.1M-22.5%	-$405.1M-6.4%	-$380.8M-34.3%	-$283.6M-36.8%	-$207.3M-18.5%	-$174.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$108.4M-8.4%	$118.4M-8.8%	$129.7M-4.2%	$135.4M-3.9%	$140.9M-10.5%	$157.5M-29.6%	$223.8M-8.1%	$243.6M
Current Assets	$88.0M-10.0%	$97.7M-10.3%	$108.9M-5.1%	$114.8M-4.4%	$120.2M-12.0%	$136.5M-32.6%	$202.5M-8.8%	$222.1M
Cash & Equivalents	$86.6M-9.3%	$95.5M-10.0%	$106.1M-5.6%	$112.4M-4.2%	$117.3M-8.7%	$128.6M-13.7%	$149.0M-28.1%	$207.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$40.2M-8.5%	$44.0M-8.7%	$48.2M+1.6%	$47.4M+256.0%	$13.3M+12.6%	$11.8M-79.3%	$57.1M+4.6%	$54.6M
Current Liabilities	$40.1M-8.5%	$43.8M-8.8%	$48.0M+1.5%	$47.3M+257.6%	$13.2M+12.7%	$11.8M-79.4%	$57.0M+4.5%	$54.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$68.1M-8.4%	$74.4M-8.8%	$81.6M-7.3%	$88.0M-31.1%	$127.6M-12.4%	$145.7M-12.6%	$166.6M-11.8%	$189.0M
Retained Earnings	-$506.4M-2.1%	-$496.1M-2.6%	-$483.5M-2.3%	-$472.7M-10.3%	-$428.5M-5.8%	-$405.1M-7.3%	-$377.5M-8.0%	-$349.6M

FLNA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$32.3M+72.4%	-$116.9M-42.6%	-$82.0M-5.8%	-$77.5M-156.7%	-$30.2M-461.1%	-$5.4M
Capital Expenditures	$581K+464.1%	$103K-75.1%	$414K-84.7%	$2.7M-87.8%	$22.2M	N/A
Free Cash Flow	-$32.8M+71.9%	-$117.0M-42.0%	-$82.4M-2.8%	-$80.2M-53.1%	-$52.4M	N/A
Investing Cash Flow	-$581K-464.1%	-$103K+75.1%	-$414K+84.7%	-$2.7M+87.8%	-$22.2M-6270.6%	$360K
Financing Cash Flow	-$239K-100.2%	$124.5M+4762.1%	$2.6M-94.6%	$47.8M-75.1%	$192.3M+154.9%	$75.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$8.9M+8.9%	-$9.7M-56.7%	-$6.2M-25.8%	-$4.9M+56.4%	-$11.3M+81.5%	-$61.3M-234.9%	-$18.3M-0.3%	-$18.2M
Capital Expenditures	N/A	$501K+526.3%	$80K	$0	$0-100.0%	$57K+235.3%	$17K-41.4%	$29K
Free Cash Flow	N/A	-$10.2M-62.7%	-$6.3M-27.4%	-$4.9M+56.4%	-$11.3M+81.5%	-$61.3M-234.9%	-$18.3M-0.2%	-$18.3M
Investing Cash Flow	N/A	-$501K-526.3%	-$80K	$0	$0+100.0%	-$57K-235.3%	-$17K+41.4%	-$29K
Financing Cash Flow	-$51K+84.5%	-$329K	$0	$0-100.0%	$90K-90.2%	$918K	$0-100.0%	$101.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FLNA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-122.3%-105.6pp	-16.7%+54.0pp	-70.7%-37.2pp	-33.5%-20.8pp	-12.8%-5.9pp	-6.9%
Return on Assets	-76.9%-61.4pp	-15.4%+48.7pp	-64.1%-31.6pp	-32.5%-20.3pp	-12.1%-5.4pp	-6.7%
Current Ratio	2.23-9.4	11.62+2.5	9.13-20.8	29.91+10.4	19.51-30.9	50.40
Debt-to-Equity	0.59+0.5	0.08-0.0	0.10+0.1	0.03-0.0	0.05+0.0	0.02
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-15.2%	N/A	-13.3%+37.0pp	-50.3%-31.9pp	-18.3%	N/A	-16.8%-20.0pp	3.3%
Return on Assets	-9.5%	N/A	-8.3%+24.3pp	-32.7%-16.1pp	-16.6%	N/A	-12.5%-15.0pp	2.5%
Current Ratio	2.19-0.0	2.23-0.0	2.27-0.2	2.43-6.7	9.08-2.5	11.62+8.1	3.55-0.5	4.07
Debt-to-Equity	0.590.0	0.590.0	0.59+0.1	0.54+0.4	0.10+0.0	0.08-0.3	0.34+0.1	0.29
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Filana Therapeutics profitable?

No, Filana Therapeutics (FLNA) reported a net income of -$91.0M in fiscal year 2025.

What is Filana Therapeutics's EBITDA?

Filana Therapeutics (FLNA) had EBITDA of -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Filana Therapeutics's return on equity (ROE)?

Filana Therapeutics (FLNA) has a return on equity of -122.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Filana Therapeutics's free cash flow?

Filana Therapeutics (FLNA) generated -$32.8M in free cash flow during fiscal year 2025. This represents a 71.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Filana Therapeutics's operating cash flow?

Filana Therapeutics (FLNA) generated -$32.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Filana Therapeutics's total assets?

Filana Therapeutics (FLNA) had $118.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Filana Therapeutics's capital expenditures?

Filana Therapeutics (FLNA) invested $581K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Filana Therapeutics spend on research and development?

Filana Therapeutics (FLNA) invested $26.6M in research and development during fiscal year 2025.

How many shares does Filana Therapeutics have outstanding?

Filana Therapeutics (FLNA) had 48M shares outstanding as of fiscal year 2025.

What is Filana Therapeutics's current ratio?

Filana Therapeutics (FLNA) had a current ratio of 2.23 as of fiscal year 2025, which is generally considered healthy.

What is Filana Therapeutics's debt-to-equity ratio?

Filana Therapeutics (FLNA) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Filana Therapeutics's return on assets (ROA)?

Filana Therapeutics (FLNA) had a return on assets of -76.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Filana Therapeutics's cash runway?

Based on fiscal year 2025 data, Filana Therapeutics (FLNA) had $95.5M in cash against an annual operating cash burn of $32.3M. This gives an estimated cash runway of approximately 36 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Filana Therapeutics's Piotroski F-Score?

Filana Therapeutics (FLNA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Filana Therapeutics's earnings high quality?

Filana Therapeutics (FLNA) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.